Karyopharm Therapeutics Inc.
KPTI | NASDAQ
$1.88
+$0.02 (+1.08%)
Sep 22, 2026, 1:26 PM ET · Market open
Market Data
Market Cap $42.15M
Enterprise Value $192.93M
Beta 0.96
Average Volume 1.08M
Shares Outstanding (Diluted) 28.94M
Shares Change YoY 235.71%
Institutional Ownership 83.27%
Exchange NASDAQ
ISIN US48576U2050
Price Performance
Price Change 1M -4.6%
Price Change 3M -80.7%
Price Change 6M -64.3%
Price Change YTD -74.1%
Price Change 1Y -68.2%
Price Change 3Y -89.2%
Price Change 5Y -98.0%
1M CAGR (ann.) -12.3%
1Y CAGR (ann.) -67.5%
5Y CAGR (ann.) -54.0%
All-Time CAGR -31.4%
Valuation
PE Ratio -0.14
Forward PE N/A
PEG Ratio 0.00
Forward PEG 0.00
PS Ratio 0.29
Forward PS 0.20
PB Ratio -0.13
P/FCF Ratio -0.65
P/Adj. FCF Ratio -0.55
P/OCF Ratio -0.82
EV/Sales 1.32
EV/EBIT -1.71
EV/EBITDA -1.72
EV/FCF -2.95
Earnings Yield -702.7%
FCF Yield -155.0%
Adj. FCF Yield -182.6%
Financial Health
Net Debt $144.53M
Total Debt $215.89M
Cash & Short-Term Investments $65.11M
Total Assets $111.32M
Current Ratio 0.79
Quick Ratio 0.76
Debt / Equity Ratio -0.65
Debt / EBITDA -1.92
Debt / FCF -3.30
OCF / Debt -0.30
Interest Coverage -1.67
Altman Z-Score -25.52
Piotroski F-Score 2
Margins & Profitability
Gross Profit Margin 95.9%
Operating Profit Margin -56.2%
EBITDA Margin -120.0%
Net Profit Margin -153.3%
FCF Margin -44.6%
Adj. FCF Margin -52.5%
SBC / Revenue 7.9%
SBC Impact (per share) -17.8%
Returns
Return on Assets -201.9%
Return on Equity 77.6%
Return on Invested Capital 376.9%
Return on Capital Employed 359.4%
Return on Tangible Assets -201.9%
Historical Growth (CAGR)
Revenue CAGR 3Y 0.1%
Revenue CAGR 5Y 7.5%
Revenue CAGR 10Y 97.9%
EPS CAGR 3Y 18.2%
EPS CAGR 5Y -21.8%
EPS CAGR 10Y 16.4%
FCF CAGR 3Y 32.7%
FCF CAGR 5Y 5.3%
FCF CAGR 10Y 4.0%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 20
EPS Growth Next 3Y 35.1%
Revenue Growth Next 3Y 68.8%
Earnings Date Nov 1, 2026
EPS Estimate (next Q) -$1.16
EPS Growth Est (next Q) -69.6%
Revenue Est (next Q) $33.54M
Revenue Growth Est (next Q) -23.9%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $9.50
Price Target Upside 410.8%
Cash Flow
Operating Cash Flow $-65.35M
Free Cash Flow $-65.35M
Adj. Free Cash Flow $-76.99M
FCF Per Share -$2.26
OCF Per Share -$2.26
OCF/S Ratio -44.6%
Income Statement
Revenue $146.62M
Gross Profit $140.58M
Operating Income $-82.35M
EBITDA $-112.46M
Net Income $-224.74M
EPS (Diluted) -$13.07
Revenue / Employee $643.07K
Profit / Employee $-985.7K
Employees 228
Add to Watchlist
Select watchlists to add or remove KPTI